Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 510

Results For "MP"

10753 News Found

Health Ministry releases
Policy | September 10, 2024

Health Ministry releases "Health Dynamics of India (Infrastructure and Human Resources) 2022-23"

The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions


Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial
Clinical Trials | September 10, 2024

Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial

TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population


Briefs: Wanbury and Bafna Pharmaceuticals
News | September 10, 2024

Briefs: Wanbury and Bafna Pharmaceuticals

Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API


Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform
News | September 10, 2024

Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform

Agreement further expands Aptar Pharma’s leading respiratory portfolio


Aster Health Academy to offer advanced medical courses
News | September 10, 2024

Aster Health Academy to offer advanced medical courses

The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation


Briefs: Ami Organics and Dr. Reddy’s Laboratories
Drug Approval | September 09, 2024

Briefs: Ami Organics and Dr. Reddy’s Laboratories

Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.


Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial
Clinical Trials | September 09, 2024

Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients


Lilly and EVA Pharma collaborate to expand access to baricitinib across 49 low- to middle-income countries in Africa
News | September 09, 2024

Lilly and EVA Pharma collaborate to expand access to baricitinib across 49 low- to middle-income countries in Africa

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases


KIMS Hospitals, Hyderabad expands into Kerala
Healthcare | September 07, 2024

KIMS Hospitals, Hyderabad expands into Kerala

The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur


Health Ministry approves introduction of new shorter, more efficacious treatment regimen for drug-resistant TB
Healthcare | September 07, 2024

Health Ministry approves introduction of new shorter, more efficacious treatment regimen for drug-resistant TB

The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure